Tharimmune, Inc. released pharmacokinetic (PK) and metabolism data from its Phase 1 study of TH104 on May 6, 2025. The study involved a buccal film formulation of nalmefene in healthy subjects.
This data provides important insights into how TH104 is absorbed, distributed, metabolized, and excreted in the body. The positive findings further support the drug's profile and its potential efficacy.
The company highlighted the advancement of TH104 for the proposed indication of temporary prophylaxis against respiratory and/or central nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids, following recent positive FDA feedback.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.